BCL-2 EXPRESSION WITH RESPECT TO ITS PROGNOSIS IN AMONGST BREAST CARCINOMA

Abstract

Breast cancer is the most common cancer among women worldwide, with the B-cell lymphoma 2 gene (BCL-2) gene being linked to favorable clinical outcomes. BCL-2 expression correlates with hormone receptor positivity, particularly estrogen receptor (ER) expression, and is more prevalent in luminal A and luminal B subtypes. Its prognostic value is most pronounced in ER-positive disease but may extend to certain triple-negative breast cancers. Understanding BCL-2's context-dependent behavior can enhance prognostic accuracy and inform therapeutic decision-making. Future research may integrate BCL-2 assessment with genomic profiling and multi-parametric risk models.